MarketCapTrends
ACRS
Aclaris Therapeutics, Inc. (ACRS)
NASDAQ · Healthcare

Aclaris Therapeutics, Inc. Shareholder Equity 2017–2025

Aclaris Therapeutics, Inc. annual/quarterly shareholder equity history from 2017 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.

  • Aclaris Therapeutics, Inc. shareholder equity for the quarter ending December 31, 2025 were 103.1M, a 33.73% decrease year-over-year.
  • Aclaris Therapeutics, Inc. shareholder equity for 2025 were 103.1M, a 33.73% decrease from 2024.
  • Aclaris Therapeutics, Inc. shareholder equity for 2024 were 155.6M, a 1.03% decrease from 2023.
  • Aclaris Therapeutics, Inc. shareholder equity for 2023 were 157.2M, a 20.46% decrease from 2022.
  • Aclaris Therapeutics, Inc. shareholder equity for 2022 were 197.6M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
Aclaris Therapeutics, Inc. Annual Shareholder Equity (Millions of US $)
2025$103
2024$156
2023$157
2022$198
2021$197
2020$38
2019$70
2018$215
2017$225
Aclaris Therapeutics, Inc. Quarterly Shareholder Equity (Millions of US $)
2025-12-31$103
2024-12-31$156
2023-12-31$157
2022-12-31$198
2021-12-31$197
2020-12-31$38
2019-12-31$70
2018-12-31$215
2017-12-31$225

Aclaris Therapeutics, Inc. Shareholder Equity — FAQ

Aclaris Therapeutics, Inc. (ACRS) shareholder equity over the last 9 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see ACRS's shareholder equity history?

The chart and table above show Aclaris Therapeutics, Inc.'s shareholder equity by year and by quarter, including the growth rate.